Icecure Medical (ICCM) has released an update.
IceCure Medical Ltd. has been granted a new U.S. patent for its innovative cryogenic pump technology, expanding the company’s leading position in cryoablation technologies for tumor treatment. With over 50 patents worldwide, this latest patent enhances IceCure’s platform, allowing broader applications in medical procedures and indicating strong potential for future growth. The company’s advanced cryoablation systems, including the flagship ProSense system, offer a minimally invasive alternative for tumor removal and are sold globally.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
